MCM
ANIK icon

MAI Capital Management’s Anika Therapeutics ANIK Stock Holding History

MAI Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,691
Closed -$24.5K – 2217
2026
Q1 		$24.5K Buy
1,691
+386
+30% +$4.48K ﹤0.01% 2673
2025
Q4 		$12.5K Buy
1,305
+11
+0.9% +$105 ﹤0.01% 2749
2025
Q3 		$12.2K Hold
1,294
– – ﹤0.01% 2663
2025
Q2 		$13.7K Hold
1,294
– – ﹤0.01% 2559
2025
Q1 		$19.4K Buy
+1,294
New +$21.5K ﹤0.01% 2191

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

MAI Capital Management's ANIK Position: Q2 2026 in Review

MAI Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2026, closing a stake of 1,691 shares — an estimated $24.5K sold.

MAI Capital Management first reported a position in ANIK in Q1 2025 and held it in 5 quarters. The position peaked at $24.5K in Q1 2026. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • MAI Capital Management reported no remaining Anika Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,691 Anika Therapeutics shares in Q2 2026, an estimated $24.5K.
  • MAI Capital Management first reported a position in Anika Therapeutics in Q1 2025 and held it in 5 quarters.
  • MAI Capital Management's Anika Therapeutics position peaked at $24.5K in Q1 2026.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.